Balyasny Asset Management LLC Rhythm Pharmaceuticals, Inc. Transaction History
Balyasny Asset Management LLC
- $54.9 Billion
- Q2 2024
Shares
2 transactions
Others Institutions Holding RYTM
# of Institutions
178Shares Held
69.1MCall Options Held
467KPut Options Held
224K-
Primecap Management CO Pasadena, CA7.31MShares$375 Million0.22% of portfolio
-
Black Rock Inc. New York, NY6.74MShares$346 Million0.01% of portfolio
-
Baker Bros. Advisors LP New York, NY6.4MShares$329 Million3.49% of portfolio
-
Ra Capital Management, L.P. Boston, MA6.08MShares$312 Million3.77% of portfolio
-
Goldman Sachs Group Inc New York, NY5.29MShares$272 Million0.04% of portfolio
About RHYTHM PHARMACEUTICALS, INC.
- Ticker RYTM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,720,000
- Market Cap $2.86B
- Description
- Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convert...